Adc Therapeutics SA Form 4 insider transactions

ADC Therapeutics SA Director Viviane Monges was granted 40,000 common shares as part of her annual equity compensation, vesting in one year.

ADC Therapeutics SA Director Ron Squarer was granted 40,000 Restricted Stock Units as part of his annual compensation, increasing his direct beneficial ownership to 108,811 common shares.

Hans Peter Wild reports acquiring 9,788,944 common shares of ADC Therapeutics SA on May 15, 2025.

Thomas Pfisterer, a director of ADC Therapeutics SA, reported a change in beneficial ownership of common shares due to an intra-group transfer following his departure from the boards of MH and HPWH.

CEO Ameet Mallik disposed of 26,758 common shares of ADC Therapeutics SA to cover tax obligations related to vesting restricted share units.

Peter J. Graham, Chief Legal Officer of ADC Therapeutics SA, acquired 220,000 common shares on February 13, 2025, at a price of $1.61 per share.

Chief Medical Officer Mohamed Zaki acquired 230,000 common shares of ADC Therapeutics SA on February 13, 2025, through a restricted share unit award.

Lisa Michelle Kallebo, Chief Accounting Officer of ADC Therapeutics SA, acquired 41,900 common shares through a restricted share unit award on February 13, 2025.

Jose Carmona, CFO of ADC Therapeutics SA, reports the acquisition of 240,000 common shares on February 13, 2025, at a price of $1.61 per share.

A Form 4 filing reveals that ADC Therapeutics CEO Ameet Mallik acquired 650,000 common shares on February 13, 2025, as part of a restricted share unit award.

Redmile Group, along with related entities, has increased its holdings in ADC Therapeutics through a series of open market purchases of common shares.

ADC Therapeutics' Chief Medical Officer, Mohamed Zaki, sold 37,112 common shares to cover tax obligations related to vesting restricted share units.

Lisa Michelle Kallebo, Chief Accounting Officer of ADC Therapeutics SA, sold 6,503 common shares to cover tax obligations related to vesting restricted share units.

ADC Therapeutics' Chief Financial Officer, Jose Carmona, sold 48,108 common shares to cover tax obligations related to vesting restricted share units.

Peter Graham, Chief Legal Officer of ADC Therapeutics, sold 41,458 common shares to cover tax obligations related to vesting restricted share units.

ADC Therapeutics CEO, Ameet Mallik, sold 238,343 common shares to cover tax obligations related to vesting restricted share units.

Redmile Group engaged in cross trades involving ADC Therapeutics common shares and pre-funded warrants, with no change in their aggregate beneficial ownership.

Redmile Group, LLC, along with related entities and individuals, reports acquiring 800,000 common shares of ADC Therapeutics SA at $2.81 per share.

Director Robert Azelby sold 6,995 common shares of ADC Therapeutics SA on June 17, 2024, to cover tax withholding obligations related to the vesting and settlement of restricted share units.

Jean-Pierre Bizzari, a director of ADC Therapeutics SA, sold 6,995 common shares to cover tax withholding obligations related to the vesting and settlement of restricted share units.

Director Peter Hug sold 1,193 common shares of ADC Therapeutics SA on June 17, 2024, to cover tax withholding obligations related to the vesting and settlement of restricted share units.

Director Viviane Monges sold 1,437 common shares of ADC Therapeutics SA on June 17, 2024, to cover tax withholding obligations related to the vesting and settlement of restricted share units.

Director Thomas Pfisterer sold 1,437 common shares of ADC Therapeutics SA to cover tax withholding obligations related to the vesting and settlement of restricted share units.

Director Victor Sandor sold 6,995 common shares of ADC Therapeutics SA to cover tax withholding obligations related to the vesting and settlement of restricted share units.

Director Ron Squarer sold 6,995 common shares of ADC Therapeutics SA on June 17, 2024, to cover tax withholding obligations related to the vesting of restricted share units.

Director Robert Azelby received a grant of 40,000 restricted stock units and disposed of 60,000 common shares of ADC Therapeutics SA on June 13, 2024.

Director Jean-Pierre Bizzari received 40,000 restricted stock units (RSUs) from ADC Therapeutics as part of the annual grant under the 2019 Equity Incentive Plan.

Director Peter Hug acquired 40,000 common shares of ADC Therapeutics SA through a grant of restricted stock units.

Director Thomas Pfisterer reports acquisition of 40,000 common shares via restricted stock units and disposal of 451,856 common shares held indirectly.

Director Victor Sandor acquired 40,000 restricted stock units (RSUs) in ADC Therapeutics SA, vesting in one year, while disposing of 87,881 common shares.